Lead Product(s) : Sirolimus
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Palvella Expands Phase 3 SELVA Trial of Qtorin Rapamycin Gel to Younger Kids
Details : Qtorin rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for the treatment of microcystic lymphatic malformations.
Product Name : Qtorin Rapamycin
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 10, 2025
Lead Product(s) : Sirolimus
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sirolimus
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Qtorin (rapamycin) a topical mTOR inhibitor, which is being investigated for the treatment of microcystic lymphatic malformations and in individuals with basal cell carcinomas (BCCs) in gorlin syndrome (GS).
Product Name : Qtorin
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 20, 2023
Lead Product(s) : Sirolimus
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable